The importance of outsourcing to Life Science R&D companies as they seek capital efficiency, speed to proof-of-concept data to unlock further investments and partnering has never been greater.
The emergence of China in particular as a major source of innovation and outsourcing options has created significant opportunity and competition in the R&D space, with nearly 50% of all Pharma R&D investment being deployed there in 2025 as reported in the recent EY Beyond Borders report.
This seminar will share and discuss insights on how companies can engage in these options in practice to achieve faster, better, cheaper value creation by leveraging external providers and partners in a compliant and effective way.
*Proposed agenda:
10:00 — Registration & Coffee
10:20 — Welcome & Introductions
10:30 — Capital Efficiency: Strategic outsourcing and what is the impact of China on Biotech R&D approaches?
11:15 — Ensuring the right contractual framework:
As biotech companies increasingly rely on external R&D partners to drive speed and capital efficiency, getting the contractual framework right is critical. Rachel Bradley, partner at Penningtons Manches Cooper, will highlight the key issues to consider when structuring outsourcing and partnering arrangements, including scope, milestones, payment terms, IP, confidentiality, liability and termination rights.
12:00 — Comfort Break
12:15 — Working with a Chinese CRO to maximise value creation and deals
13:00 — Networking Lunch
14:00 — Close
*Subject to change.
